Illumina closed its acquisition of SomaLogic and related assets in a cash deal that expands the company's move into proteomics and multiomics. The transaction transfers SomaLogic technologies and Boulder facilities to Illumina while preserving near-term service agreements and milestone structures. Illumina will integrate SomaLogic’s aptamer-based proteomics capability with its sequencing ecosystem and software stack to offer protein analysis at scale. Company commentary highlights the intent to combine SomaLogic’s assay platform with Illumina’s NGS infrastructure and DRAGEN analytics to create a high-throughput, sequencing‑based proteomics offering. The deal is positioned as a step toward integrated multiomics workflows that could accelerate biomarker discovery and clinical proteomics adoption; Illumina plans to maintain operations in Boulder while aligning the acquired tech with its broader product roadmap.